FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma By Ogkologos - January 10, 2025 788 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR New on NCI’s Websites for March 2022 March 16, 2022 ¿Tener paneles solares o vivir cerca de una granja solar puede... April 6, 2023 When Prenatal DNA Tests Point to Cancer May 17, 2023 EMA Recommends Extension of Therapeutic Indications for Selpercatinib August 25, 2022 Load more HOT NEWS A Phase III Study of Spartalizumab in Combination with Dabrafenib and... EMA Recommends Granting a Marketing Authorisation for Inavolisib Commemorating and Making History: The National Cancer Act 50th Anniversary Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer
